Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine

Learn more about:
Related Clinical Trial
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine ‘Typhocon’ in Bangladesh Effectiveness of a Typhoid Conjugate Vaccine in DRC Transcriptomic Responses for the Identification of Pathogens Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants Commercial Typhoid Tests Validation Trial Commercial Typhoid Tests Validation WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Safety and Immunogenicity of Typhax, a Typhoid Vaccine Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Investigating Enteric Fever – Salmonella Typhi and Paratyphi Challenge Study Induction of Gut Permeability by an Oral Vaccine Studies of Immune Responses to Orally Administered Vaccines in Developing Country Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants Typhoid Fever: Combined vs. Single Antibiotic Therapy Vaccines Against Salmonella Typhi Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults CVD 909 Vi Prime Boost Study Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Understanding Typhoid Disease After Vaccination Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood Global Genomic and Proteomic Profiling of African Children With Typhoid Fever

Brief Title

Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine

Official Title

A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV® in Healthy 6 Months-45 Years Aged Nepalese Participants.

Brief Summary

      This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in
      healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose.

      The study objectives are:

      I. Demonstrate non-inferiority of Vi-DT compared to Typbar TCV® as measured by seroconversion
      rates of anti-Vi IgG ELISA antibody titers, 4 weeks after single dose (pooled immunogenicity
      of three lots of Vi-DT)

      II. Demonstrate the equivalence of immunogenicity as measured by anti-Vi IgG GMT of three
      lots of Vi-DT vaccine 4 weeks after single dose.

Detailed Description

      Subjects will be stratified according to age. The study procedure is as follows:

      Visit 1 (day-1 to -7): Screen participants by medical/medications history, physical
      examination, Vital signs, Urine pregnancy test (UPT)

      Visit 2 (day 0): Enroll, randomize and administer vaccine to eligible participants and assess
      participant safety by physical examination and Vital signs, Collect blood for immunogenicity

      Visit 3 (day 7): Check solicited adverse reaction 7 days post vaccination and Assess
      participant safety by physical examination and Vital signs

      Visit 4 (day 28): Assess participant safety by physical examination and Vital signs, Collect
      blood for immunogenicity assessments

      Visit 5 (day 84): Assess participant safety by physical examination and Vital signs

      Visit 6 (day 168): Assess participant safety by physical examination and Vital signs, Collect
      blood for immunogenicity assessments, and fill in study completion form in the absence of any
      safety concern.

      This study is observer-blind: vaccine administrator and vaccine safety evaluator will be two
      distinct persons to avoid bias of safety assessment. Trial staff other than the vaccine

      For retention: After vaccination, field health worker/designee will contact participant every
      day till Day 7 by physical visit or by phone call. Follow-up reminder calls will be done very
      frequently as per discretion of study staff until 24 weeks for all participant to assess
      participant safety.

Study Phase

Phase 3

Study Type


Primary Outcome

Seroconversion rate1

Secondary Outcome

 Geometric Mean Titers (GMT) 2




Test Vaccine Vi-DT Typhoid conjugate

Study Arms / Comparison Groups

 Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)
Description:  One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).
MR for age group at 9-15 months.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 15, 2019

Completion Date

January 2021

Primary Completion Date

September 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Healthy participants 6 months to 45 years of age at enrollment

          2. Participants/Parents/LAR who have voluntarily given informed consent/assent

          3. Participants/Parents/LAR willing to follow the study procedures of the study and
             available for the entire duration of the study

        Exclusion Criteria:

          1. Child with a congenital abnormality

          2. Subject concomitantly enrolled or scheduled to be enrolled in another trial

          3. Known history of immune function disorders including immunodeficiency diseases (Known
             HIV infection or other immune function disorders)

          4. Chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisone equivalent for
             periods exceeding 10 days), cytotoxic or other immunosuppressive drugs

          5. Receipt of blood or blood-derived products in the past 3 months

          6. Subject with a previously ascertained or suspected disease caused by S. Typhi

          7. Subject who have had household contact with/and or intimate exposure to an individual
             with laboratory-confirmed S. Typhi

          8. Individual who has previously received a typhoid vaccine

          9. Subject who has received or is expected to receive other vaccines from 1 month prior
             to IP vaccination to Visit 4 (approx.1 month post IP) except PVC booster as per EPI

         10. Known history or allergy to vaccines or other medications

         11. History of uncontrolled coagulopathy or blood disorders

         12. Any abnormality or chronic disease which in the opinion of the investigator might be
             detrimental for the safety of the subject and interfere with the assessment of the
             study objectives

         13. Any female participant who is lactating, pregnant* or planning for pregnancy during
             the course of study period

         14. Participants/Parents/LAR planning to move from the study area before the end of study

         15. As per Investigator's medical judgement individuals could be excluded from the study
             inspite of meeting all inclusion/exclusion criteria mentioned above

             Temporary Contraindication

         16. Acute illness, in particular infectious disease or fever (axillary temperature
             ≥37.5°C), within three days prior to enrolment and vaccination.

               -  Urine pregnancy test (UPT) will be performed in all married females prior to




6 Months - 45 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Ganesh Kumar Rai, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID

IVI T003

Responsible Party


Study Sponsor

International Vaccine Institute


 SK Bioscience Co., Ltd.

Study Sponsor

Ganesh Kumar Rai, MD, Principal Investigator, Kanti Children's Hospital

Verification Date

April 2020